Identification of novel UBE2E3::PDE1A and CTC1::MEF2C fusion transcripts in acute myeloid leukemia
Therapeutic Advances in Hematology · 2026-08 · 17
DOI: 10.1177/20406207261480375 ↗Kurz gefasst
Fallbericht in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 18.08.2026. Verfasst von Jifang Tu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a hematologic malignancy caused by the malignant proliferation and differentiation block of immature myeloid cells (blasts) in the bone marrow. The pathogenesis, diagnostic classification, treatment, and prognosis of AML are fundamentally linked to the accumulation of genetic variants, fusion gene formation, and chromosomal karyotype abnormalities. Using mRNA sequencing (next-generation sequencing, NGS), we identified and validated two novel fusion genes, UBE2E3::PDE1A and CTC1::MEF2C , in a case of AML-M2a. This patient also harbored six single nucleotide variants (SNV) ( EP300 , KRAS , NRAS , RAD21 , TET2 , and TP53 ) and complex karyotype (CK). The chromosomes exhibited extreme instability and high variability, with tumor cells containing multiple clones and showing continuous karyotype evolution as the disease progressed. The patient was treated with three chemotherapy regimens (VMA, VHAA, and Decitabine-Venetoclax), but none achieved remission. We propose that the combination of these novel fusion genes, multiple SNVs, and the complex karyotype collectively contributed to the patient’s multidrug resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Maligancies, Hangzhou, China.
- Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, China.
- Department of Hematology, Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China.
ORCID-Profile: Jifang Tu, Hongyan Tong
Zitieren
APA
Tu, J., Wang, Y., Gao, X., Wang, H., Wang, H., Jin, J., & Tong, H. (2026). Identification of novel UBE2E3::PDE1A and CTC1::MEF2C fusion transcripts in acute myeloid leukemia. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261480375
Vancouver
Tu J, Wang Y, Gao X, Wang H, Wang H, Jin J, et al. Identification of novel UBE2E3::PDE1A and CTC1::MEF2C fusion transcripts in acute myeloid leukemia. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261480375
BibTeX
@article{Tu2026,
author = {Tu, Jifang and Wang, Yungui and Gao, Xiangli and Wang, Huanping and Wang, Huafeng and Jin, Jie and Tong, Hongyan},
title = {Identification of novel UBE2E3::PDE1A and CTC1::MEF2C fusion transcripts in acute myeloid leukemia},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261480375}
}
EUVIMED